Observing Brentuximab Vedotin Treatment in Adults With Hodgkins Lymphoma After Stem Cell Transplant

What this Trial Is About

Researchers are evaluating how well brentuximab vedotin BV works for treating adults with Hodgkin lymphoma HL who have undergone or are candidates for autologous stem cell transplant ASCT. This observational study focuses on assessing BVs safety and effectiveness in real-world clinical settings before and after ASCT treatment. Approximately 70 participants will take part in this multi-center trial conducted in Poland over about 4.5 years. Participants will receive standard treatment with BV according to clinic practice and be assigned to one of two groups those receiving BV before ASCT as salvage therapy and those receiving BV after ASCT as consolidation therapy. Each participant will be observed prospectively for 24 months following the end of their BV treatment. No experimental interventions are administered as part of this study. Participants will visit the study clinic five times, spaced every 12 weeks during treatment. After treatment ends, follow-up visits will occur every three months during the first year and every four to six months during the second year. Researchers will collect data electronically and monitor progression-free survival and overall survival for up to 36 months to evaluate treatment outcomes and safety.

A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma